Table 3 Agreement between p53 immunohistochemistry and TP53 NGS analysis.

From: p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

 

(Likely) pathogenic mutation on TP53 NGS analysis

 
 

All EC

POLE wildtype and MMR proficient EC

p53 IHC

Absent

Present

Absent

Present

Wildtype

215

19

96

4

Abnormal

13

97

6

76

Total

228

116

102

80

Accuracy

90.7% (95% CI 87.6–93.8%)

94.5% (95% CI 89.4–99.6%)

Sensitivity

83.6% (95% CI 79.7–87.5%)

95.0% (95% CI 90.2–99.8%)

Specificity

94.3% (95% CI 91.8–96.7%)

94.1% (95% CI 88.9–99.3%)

  1. In bold, EC with concordant p53 IHC and sequencing for TP53 mutations.
  2. IHC immunohistochemistry, NGS next generation sequencing, EC endometrial cancer, MMR mismatch repair, CI confidence interval.
Back to article page